Discussing the VERITAC-2 (vepdegestrant) & SERENA-6 (camizestrant) ASCO data and impacts on the broader SERD landscape

Executed on:May 29, 2025 1:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Cambridge

Clinical Senior Research Associate and Academic Consultant in Breast Cancer Therapeutics at the University of Cambridge.
Currently manages 30 patients with HR+/HER- breast cancer each month.
Focus on Early phase breast cancer clinical trials with expertise in first-in-human studies & drug combination trials, new small molecule & antibody therapeutics and the development of pharmacodynamic and predictive biomarkers.

Interview Goal

This conversation will focus on the recent ASCO 2025 data on SERDS:
SERENA-6 Trial (AstraZeneca – Camizestrant - Abstract Number: LBA4) & VERITAC-2 Trial (Arvinas/Pfizer – Vepdegestrant - Abstract Number: LBA1000). We will discuss the data and the impact on the broader SERD landscape.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.